Anacor names Paul Berns president and CEO
This article was originally published in Scrip
Anacor, a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics, has named Paul Berns – currently chair of the board – president and CEO effective immediately. Mr Berns succeeds David P Perry who was Anacor's president and CEO from 2002. Mr Berns most recently served as president and CEO of Allos Therapeutics before that company's acquisition by Spectrum Pharmaceuticals in 2012.